Boehringer, Lilly's Tradjenta meets in first CV outcomes trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said Tradjenta linagliptin met the primary endpoint of improving time to first occurrence of a major cardiovascular event (MACE), including CV death, non-fatal myocardial infarction (MI) or non-fatal stroke, vs. placebo in the Phase IV CARMELINA trial to treat Type II diabetics with high CV risk.

The double-blind, international trial enrolled 6,979 adults to receive once-daily 5 mg Tradjenta or placebo in addition to standard of care (SOC). Most patients had kidney disease, a key risk factor for CV disease. Full results will be presented in October at the European Association for the Study of Diabetes meeting in Berlin...